세계의 삽입형 생체 재료 시장 예측 : 재료별, 용도별, 최종 사용자별, 지역별 분석(-2030년)

According to Stratistics MRC, the Global Implantable Biomaterials Market is accounted for $112.16 billion in 2024 and is expected to reach $255.39 billion by 2030 growing at a CAGR of 14.7% during the forecast period. Implantable biomaterials are substances designed to be placed inside the body for medical purposes, ranging from therapeutic delivery systems to tissue replacement. They are engineered to interact with biological systems without causing harm or rejection. These materials can be synthetic or natural, and their properties are tailored to specific applications, such as biocompatibility, mechanical strength, and degradation rate.

According to the Centers for Disease Control and Prevention, a US-based national public health agency, in the US, 1 in 20 adults age 20 and older have cardiovascular diseases.

Market Dynamics:

Driver:

The increase in the geriatric population

The rise in the geriatric population is a significant driver for the implantable biomaterials market due to several factors. Firstly, as people age, there's a greater likelihood of needing medical interventions such as joint replacements, dental implants, and cardiovascular implants, all of which rely on biomaterials. Secondly, older individuals often experience age-related conditions like osteoporosis or cardiovascular diseases, necessitating the use of biomaterials for treatment or support. Additionally, advancements in healthcare have led to increased life expectancy, further contributing to the demand for implantable biomaterials.

Restraint:

Limitations of biomaterial-based products

While biomaterial-based products have significantly advanced implantable medical devices, they are not without limitations. One key restraint lies in the variability of patient responses to these materials, leading to potential immune reactions or tissue rejection. Moreover, biomaterial degradation over time can compromise the device's integrity and functionality, necessitating frequent replacements or revisions. The cost associated with developing and manufacturing biomaterial-based implants is another significant barrier, often leading to higher prices for patients.

Opportunity:

Favorable reimbursements for implantable biomaterials

Favorable reimbursements for implantable biomaterials present a significant opportunity in the implantable biomaterials market. With healthcare systems increasingly covering the costs associated with these materials, patients are more inclined towards advanced and durable solutions. This drives demand and adoption, boosting market growth. Favorable reimbursements also incentivize healthcare providers to offer these innovative solutions, further expanding the market. Moreover, it encourages research and development in the field, leading to the introduction of more effective and versatile biomaterials. This trend creates a conducive environment for market expansion, benefiting both patients and industry stakeholders.

Threat:

Huge disasters or personal misfortunes for the patient

In the implantable biomaterials market, huge disasters or personal misfortunes for patients could arise from factors such as material rejection, implant failure, or infection. Material rejection occurs when the body's immune system reacts negatively to the implanted material, leading to complications and potential health risks. Implant failure can result from mechanical issues or improper integration with surrounding tissues, necessitating additional surgeries or interventions. Infections, either during or after implantation can pose serious threats to the patients' health condition and can lead to systemic complications.

Covid-19 Impact:

The COVID-19 pandemic has significantly impacted the implantable biomaterials market. Elective surgeries, including those requiring implantable biomaterials, were postponed or cancelled due to healthcare resource reallocation and safety concerns. This led to a decline in demand for such materials. Additionally, disruptions in the global supply chain and manufacturing processes affected the availability of these biomaterials. However, as healthcare systems adapt and elective procedures resume, the market is expected to gradually recover. Furthermore, increased emphasis on healthcare infrastructure resilience and innovation in biomaterial technologies may drive future growth in the market.

The metals and metal alloys segment is expected to be the largest during the forecast period

The metals and metal alloys segment in the implantable biomaterials market has experienced significant growth due to several factors. Metals like titanium and its alloys are favored for their excellent biocompatibility, corrosion resistance, and mechanical properties, making them ideal for implants such as joint replacements and dental implants. Additionally, advancements in metallurgy have led to the development of new alloys with improved performance and tailored properties, further driving the segment's growth. The increasing prevalence of orthopedic and dental disorders, coupled with an aging population seeking implants, has also contributed to the expansion of this segment.

The Orthopaedics segment is expected to have the highest CAGR during the forecast period

The orthopaedics segment within the implantable biomaterials market has experienced significant growth in recent years. This growth can be attributed to several factors. Advancements in biomaterial technology have led to the development of more durable and biocompatible materials suitable for orthopaedic implants, enhancing patient outcomes and reducing the need for revision surgeries. Additionally, an aging population worldwide has contributed to the rise in orthopaedic procedures, such as joint replacements and spinal surgeries, driving demand for implantable biomaterials. Moreover, increasing awareness among patients and healthcare providers about the benefits of these implants has fueled market expansion.

Region with largest share:

In recent years, North America has experienced notable growth in the implantable biomaterials market. This surge can be attributed to several factors, including advancements in medical technology, increased healthcare expenditure, and a growing aging population. Additionally, the rising prevalence of chronic diseases and musculoskeletal disorders has fuelled the demand for implantable biomaterials across the region. Moreover, the presence of key market players and robust research and development activities has further stimulated market expansion. Regulatory support and favourable reimbursement policies have also played a significant role in fostering market growth in North America.

Region with highest CAGR:

The Asia-Pacific region has witnessed significant growth in the implantable biomaterials market due to several factors. Rising healthcare expenditures, an increasing prevalence of chronic diseases, and a growing aging population are driving the demand for implantable medical devices. Moreover, advancements in biomaterial technology and surgical techniques have bolstered market expansion. Countries like China, India, and Japan are leading the growth trajectory, propelled by improving healthcare infrastructure and a surge in medical tourism. Additionally, favorable government initiatives and supportive regulatory frameworks have encouraged market players to invest in the region, further fueling growth.

Key players in the market

Some of the key players in Implantable Biomaterials market include 3M, Arthrex, BASF SE, Bayer AG, Berkeley Advanced Biomaterials, Biomet, Cam Bioceramics B.V., Carpenter Technology Corporation, Celanese Corporation, CeramTec, Collagen Solutions Plc, CoorsTek Inc., DuPont, Evonik Industries AG, Linden Lab, Medtronic, Royal DSM, Stryker Corporation and Zimmer Biomet Holdings.

Key Developments:

In May 2024, Zimmer Biomet Holdings, Inc., a global medical technology leader, announced the successful completion of the world's first robotic-assisted shoulder replacement surgery using its ROSA Shoulder System. The surgery was performed at Mayo Clinic by John W. Sperling, MD, MBA, Professor of Orthopedic Surgery at Mayo Clinic in Rochester, Minnesota, and a key contributor to the ROSA Shoulder development team.

In May 2024, Arecor and Medtronic say they partnered to create a new type of insulin that would allow for the use of new insulin pump designs. These new insulin pumps in mind would sit under the skin, rather than on the surface of the skin. The research collaboration aims to develop a novel, high-concentration, thermostable insulin for use by Medtronic in a next-generation pump. A new insulin of this kind could minimize the need for pump maintenance interventions and expand utility for physicians while saving costs.

Materials Covered:

• Natural Biomaterials
• Ceramics
• Metals and Metal Alloys
• Synthetic Polymers
• Composites

Applications Covered:

• Ophthalmology
• Plastic Surgery
• Wound Healing
• Cardiology
• Dental
• Orthopedics
• Other Applications

End Users Covered:

• Specialty Clinics
• Hospitals
• Ambulatory Surgical Centers
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Implantable Biomaterials Market, By Material

• 5.1 Introduction
• 5.2 Natural Biomaterials
• 5.3 Ceramics
• 5.4 Metals and Metal Alloys
• 5.5 Synthetic Polymers
• 5.6 Composites

6 Global Implantable Biomaterials Market, By Application

• 6.1 Introduction
• 6.2 Ophthalmology
• 6.3 Plastic Surgery
• 6.4 Wound Healing
• 6.5 Cardiology
• 6.6 Dental
• 6.7 Orthopedics
• 6.8 Other Applications

7 Global Implantable Biomaterials Market, By End User

• 7.1 Introduction
• 7.2 Specialty Clinics
• 7.3 Hospitals
• 7.4 Ambulatory Surgical Centers
• 7.5 Other End Users

8 Global Implantable Biomaterials Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 3M
• 10.2 Arthrex
• 10.3 BASF SE
• 10.4 Bayer AG
• 10.5 Berkeley Advanced Biomaterials
• 10.6 Biomet
• 10.7 Cam Bioceramics B.V.
• 10.8 Carpenter Technology Corporation
• 10.9 Celanese Corporation
• 10.10 CeramTec
• 10.11 Collagen Solutions Plc
• 10.12 CoorsTek Inc.
• 10.13 DuPont
• 10.14 Evonik Industries AG
• 10.15 Linden Lab
• 10.16 Medtronic
• 10.17 Royal DSM
• 10.18 Stryker Corporation
• 10.19 Zimmer Biomet Holdings